Risk Assessment of Thromboembolic Disease In Patients Treated For Multiple Myeloma

被引：0
|
作者：
Douma, Soukaina [1 ]
Naim, Sara [1 ]
Benmoussa, Amine [1 ]
Berrada, Sophia [1 ]
Lamchahab, Mouna [1 ]
Khoubila, Nissrine [1 ]
Rachid, Mohammed [1 ]
Qachouh, Meryem [1 ]
Cherkaoui, Siham [1 ]
Madani, Abdellah [1 ]
机构：
[1] Univ Hosp, Ctr IBN ROCHD, Casablanca, Morocco
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-556
引用
收藏
页码：S570 / S570
页数：1
相关论文
共 50 条
  • [1] Risk assessment tools of thromboembolic events in multiple myeloma patients treated with immunomodulators
    Le Rigoleur, Astrid
    Beltjens, Magali
    Descamps, Olivier
    Kentos, Alain
    ACTA CLINICA BELGICA, 2021, 76 : 46 - 46
  • [2] Risk Factors and Risk Stratification of Thromboembolic Risk in Patients with Multiple Myeloma
    Chaireti, Roza
    Nahi, Hareth
    Mazzucato, Mario
    HEMATO, 2022, 3 (03): : 518 - 526
  • [3] Evaluation of the use of apixaban in prevention of thromboembolic disease in patients with myeloma treated with iMiDs
    Gavard, M.
    Pegourie, B.
    Pernod, G.
    Rolland-Neyret, V.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 51 - 51
  • [4] Risk factors for thromboembolic events in multiple myeloma patients treated with IMiDs-based therapy while on LMWH prophylaxis
    Leleu, X.
    Iacobelli, S.
    Barrois, A.
    van Os, M.
    Clark, L.
    Moreau, P.
    Dib, M.
    Caillot, D.
    Niederwieser, D.
    Masszi, T.
    Fontan, J.
    Michallet, M.
    Doyen, C.
    Hajek, R.
    Onida, F.
    Ludwig, H.
    de Witte, T.
    Schoenland, S.
    Gahrton, G.
    Morris, C.
    Kroeger, N.
    Garderet, L.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S205 - S206
  • [5] What is the best preventive treatment for thromboembolic complications in patients treated with thalidomide for multiple myeloma?
    Macro, Margaret
    HEMATOLOGIE, 2011, 17 (03): : 176 - 177
  • [6] Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients
    Delcroix, Marion
    Staehler, Gerd
    Gall, Henning
    Gruenig, Ekkehard
    Held, Matthias
    Halank, Michael
    Klose, Hans
    Vonk-Noordegraaf, Anton
    Rosenkranz, Stephan
    Pepke-Zaba, Joanna
    Opitz, Christian F.
    Gibbs, J. Simon R.
    Lange, Tobias J.
    Tsangaris, Iraklis
    Huscher, Doerte
    Pittrow, David
    Olsson, Karen M.
    Hoeper, Marius M.
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (05)
  • [7] The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma
    Fan, Huishou
    Yan, Wenqiang
    Xu, Jingyu
    Du, Chenxing
    Sui, Weiwei
    Deng, Shuhui
    Zou, Dehui
    Qiu, Lugui
    An, Gang
    BLOOD, 2022, 140 : 4371 - 4373
  • [8] Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab
    Ye, Zhan
    Wolf, Laurie A.
    Mettman, Daniel
    Plapp, Fred, V
    VOX SANGUINIS, 2020, 115 (02) : 207 - 212
  • [9] Bleeding Risk in Patients with Multiple Myeloma Treated for Venous Thromboembolism
    Herrera, Diego Adrianzen
    Lutsey, Pamela L.
    Giorgio, Katherine
    Zakai, Neil A.
    BLOOD, 2021, 138
  • [10] Risk of RBC Alloimmunization in Multiple Myeloma Patients Treated by Daratumumab
    Ye, Zhan
    Wolf, Laurie
    Plapp, Fred
    TRANSFUSION, 2018, 58 : 188A - 188A
12345